Fig. 2

EmB-MO improved the pathological symptoms in mice with DSS-induced ulcerative colitis. A Daily changes in body weight (A-1) and disease activity index (DAI) (A-2) in the indicated group. B Macroscopic observation of colon (B-1) and the ratio of colon weight to length (B-2). C Macroscopic observation of spleen (C-1) and the ratio of spleen to body weight (C-2). Data represent the mean ± standard error of the mean (n ≥ 6). ^***P < 0.001 vs. control group, ^#P < 0.05, ^##P < 0.01, ^###P < 0.001 vs. ulcerative colitis group. 5-ASA: 5-aminosalicylic acid, 100 mg/kg/d; Em: Emodin, 8 mg/kg/d; EmB-L: Emodin-borate nanoparticles, 3 mg/kg/d; EmB-H: 6 mg/kg/d; EmB-MO-L: EmB modified with oligomeric mannitol into microgels, 3 mg/kg/d; and EmB-MO-H: 6 mg/kg/d